Wall Street brokerages forecast that Natera, Inc. (NASDAQ:NTRA) will report ($1.05) earnings per share for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Natera’s earnings, with the highest EPS estimate coming in at ($0.98) and the lowest estimate coming in at ($1.13). Natera posted earnings of ($0.45) per share in the same quarter last year, which would suggest a negative year over year growth rate of 133.3%. The company is scheduled to report its next quarterly earnings results on Wednesday, May 5th.
On average, analysts expect that Natera will report full year earnings of ($4.24) per share for the current financial year, with EPS estimates ranging from ($4.39) to ($4.10). For the next financial year, analysts forecast that the firm will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.89) to ($2.40). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Natera.
Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 25th. The medical research company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.28). Natera had a negative return on equity of 53.39% and a negative net margin of 52.11%.
A number of analysts have weighed in on NTRA shares. Craig Hallum increased their target price on shares of Natera from $92.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, January 4th. SVB Leerink upped their price target on shares of Natera from $95.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 20th. BTIG Research upped their price target on shares of Natera from $112.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, January 19th. Morgan Stanley upped their price target on shares of Natera from $87.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, March 8th. Finally, Canaccord Genuity increased their target price on shares of Natera from $112.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, January 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $102.33.
In other Natera news, Director Todd C. Cozzens sold 29,475 shares of the company’s stock in a transaction dated Tuesday, March 9th. The shares were sold at an average price of $100.35, for a total transaction of $2,957,816.25. Following the completion of the sale, the director now directly owns 36,753 shares of the company’s stock, valued at $3,688,163.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Steven Leonard Chapman sold 8,155 shares of the company’s stock in a transaction dated Wednesday, January 13th. The shares were sold at an average price of $115.00, for a total transaction of $937,825.00. Following the sale, the chief executive officer now directly owns 38,282 shares of the company’s stock, valued at $4,402,430. The disclosure for this sale can be found here. Insiders have sold 151,010 shares of company stock valued at $15,014,023 over the last ninety days. Insiders own 9.29% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Capstone Triton Financial Group LLC purchased a new stake in shares of Natera in the fourth quarter worth approximately $37,000. Harvest Fund Management Co. Ltd acquired a new position in Natera during the fourth quarter valued at approximately $39,000. James Investment Research Inc. acquired a new position in Natera during the fourth quarter valued at approximately $50,000. Heritage Wealth Advisors grew its holdings in Natera by 18.8% during the fourth quarter. Heritage Wealth Advisors now owns 855 shares of the medical research company’s stock valued at $85,000 after purchasing an additional 135 shares during the last quarter. Finally, Sittner & Nelson LLC acquired a new position in Natera during the fourth quarter valued at approximately $100,000. 94.93% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:NTRA traded down $2.02 on Monday, reaching $102.96. 15,304 shares of the company’s stock were exchanged, compared to its average volume of 878,422. The firm has a market capitalization of $8.91 billion, a price-to-earnings ratio of -43.31 and a beta of 1.66. Natera has a fifty-two week low of $28.30 and a fifty-two week high of $127.19. The business’s 50-day moving average is $105.17 and its two-hundred day moving average is $95.73. The company has a quick ratio of 4.57, a current ratio of 4.68 and a debt-to-equity ratio of 0.37.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com